{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:38:18Z","timestamp":1791434298619,"version":"4.3.3"},"reference-count":69,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2011,9,30]]},"DOI":"10.2217\/fon.11.81","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T19:42:24Z","timestamp":1316115744000},"page":"1035-1043","source":"Crossref","is-referenced-by-count":82,"title":["Ruxolitinib: A New JAK1\/2 Inhibitor That Offers Promising Options for Treatment of Myelofibrosis"],"prefix":"10.1080","volume":"7","author":[{"given":"Alen","family":"Ostojic","sequence":"first","affiliation":[{"name":"Department of Hematology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Merkur, University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia, UT MD Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX77030, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209053630"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810801)48:3<866::AID-CNCR2820480334>3.0.CO;2-Y"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01357.x"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00023-7"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1976.tb140817.x"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404693"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2319"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074368"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13346"},{"issue":"6","key":"e_1_3_2_3_12_1","first-page":"363","article-title":"Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.","volume":"25","author":"Randi ML","year":"1994","unstructured":"Randi ML , BarboneE, FabrisF, VarottoL, MacriC, GirolamiA. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.J. Med.25(6), 363\u2013369 (1994).","journal-title":"J. Med."},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9525(00)89000-9"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099184"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405097"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270108"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194548"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2226"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0532-x"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-8-929"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3264"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.10.015"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3905.3905"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.2804.2804"},{"issue":"12","key":"e_1_3_2_3_39_1","first-page":"863","article-title":"Inflammation research association \u2013 15th international conference advances in asthma and COPD and other inflammatory diseases.","volume":"11","author":"Walker K","year":"2008","unstructured":"Walker K . Inflammation research association \u2013 15th international conference advances in asthma and COPD and other inflammatory diseases.IDrugs11(12), 863\u2013865 (2008).","journal-title":"IDrugs"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3538.3538"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.033787"},{"issue":"1","key":"e_1_3_2_3_44_1","first-page":"PIII","article-title":"The effect of various degrees of hepatic dysfunction on the pharmacokinetics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA.","volume":"87","author":"Chen X","year":"2010","unstructured":"Chen X , ShiJ, McgeeRet al. The effect of various degrees of hepatic dysfunction on the pharmacokinetics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA. Clin. Pharmacol. Ther. 87(Suppl. 1), PIII\u201359 (2010) (Abstract).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"e_1_3_2_3_45_1","first-page":"PII","article-title":"Effects of various degrees of renal impairment and hemodialisis on the pharmacokinetics and pharmacodynamics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA.","volume":"87","author":"Shi J","year":"2010","unstructured":"Shi J , ChenX, McgeeRet al. Effects of various degrees of renal impairment and hemodialisis on the pharmacokinetics and pharmacodynamics of INCB018424. The 111th ASCPT meeting, Atlanta, GA, USA. Clin. Pharmacol. Ther. 87(Suppl. 1), PII\u201353 (2010) (Abstract).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"e_1_3_2_3_46_1","first-page":"9","article-title":"An open-label assessment of the effects of rifampin, a potent CYP3A4 inducer on the PK\/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA.","volume":"49","author":"Shi J","year":"2009","unstructured":"Shi J , ChenX, YeleswaramSet al. An open-label assessment of the effects of rifampin, a potent CYP3A4 inducer on the PK\/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA. J. Clin. Pharmacol. 49(9), 9 (2009) (Abstract).","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"e_1_3_2_3_47_1","first-page":"10","article-title":"An open-label assessment of the effects of CYP3A4 inhibitors on the PK\/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA.","volume":"49","author":"Shi J","year":"2009","unstructured":"Shi J , ChenX, YeleswaramSet al. An open-label assessment of the effects of CYP3A4 inhibitors on the PK\/PD of INCB018424 in healthy subjects. The 38th ACCP meeting, San Antonio, TX, USA. J. Clin. Pharmacol. 49(9), 10 (2009) (Abstract).","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011405663"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389469"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"crossref","unstructured":"Verstovsek S MesaR GotlibJet al. Results of COMFORT-I a randomized double-blind Phase III trial of JAK1\/2 inhibitor INCB18424 (424) vs placebo (PB) for patients with myelofibrosis (MF). The 47th ASCO Meeting . Chicago IL USA. J. Clin. Oncol. (2011) (Abstract 6500).","DOI":"10.1200\/jco.2011.29.15_suppl.6500"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.311.311"},{"key":"e_1_3_2_3_55_1","unstructured":"Williams W ScherleP ShiJet al. A randomized placebo-controlled study of INCB018424 a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Presented at: The 72nd ACR Meeting . San Francisco CA USA 714 (2008) (Abstract)."},{"issue":"1","key":"e_1_3_2_3_56_1","first-page":"261","article-title":"Novel mechanism for topical treatment of plaque psoriasis \u2013 results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1\/2 inhibitor INCB018424 cream. The 70th SID meeting, Atlanta, GA, USA.","volume":"130","author":"Callis Duffin K","year":"2010","unstructured":"Callis Duffin K , LuchiM, Fidelus-GortRet al. Novel mechanism for topical treatment of plaque psoriasis \u2013 results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1\/2 inhibitor INCB018424 cream. The 70th SID meeting, Atlanta, GA, USA. J. Invest. Dermatol. 130(Suppl. 1), 261 (2010) (Abstract).","journal-title":"J. Invest. Dermatol."},{"key":"e_1_3_2_4_2_1","unstructured":"Press release. Incyte announces major collaboration and license agreement for two hematology-oncology programs (2009) investor.incyte.com\/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1359169&highlight=."},{"key":"e_1_3_2_4_3_1","unstructured":"Media releases. Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers (2009) www.novartis.com\/newsroom\/media-releases\/en\/2009\/1357027.shtml"},{"key":"e_1_3_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_3_2_4_5_1","unstructured":"Media release. Second Phase III study of Novartis JAK inhibitor INC424 meets primary end point in patients with myelofibrosis (2011) www.novartis.com\/newsroom\/media-releases\/en\/2011\/1496848.shtml"},{"key":"e_1_3_2_4_6_1","unstructured":"ClinicalTrials.gov NCT00509899 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_7_1","unstructured":"ClinicalTrials.gov NCT00952289 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_8_1","unstructured":"ClinicalTrials.gov NCT00934544 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_9_1","unstructured":"ClinicalTrials.gov NCT01243944 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_10_1","unstructured":"ClinicalTrials.gov NCT00674479 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_11_1","unstructured":"ClinicalTrials.gov NCT01251965 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_12_1","unstructured":"ClinicalTrials.gov NCT01164163 (2011) http:\/\/clinicaltrials.gov"},{"key":"e_1_3_2_4_13_1","unstructured":"US FDA: Orphan drug product designations and approvals search (2011) www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm"},{"key":"e_1_3_2_4_14_1","unstructured":"European Medicines Agency: Rare diseases designations (2011) www.ema.europa.eu"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.11.81","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:41:26Z","timestamp":1719124886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.11.81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,15]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9,30]]}},"alternative-id":["10.2217\/fon.11.81"],"URL":"https:\/\/doi.org\/10.2217\/fon.11.81","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,15]]}}}